Evaluation of a fixed alternating treatment in patients with advanced breast cancer.

D. L. Ahmann, J. O'Fallon, M. J. O'Connell, H. F. Bisel, R. G. Hahn, S. Frytak, J. H. Edmonson, J. Rubin, J. N. Ingle, L. K. Kvols

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A total of 128 patients were randomly assigned to two induction treatment programs: Adriamycin and L-PAM versus Cytoxan, 5-Fluorouracil, and Prednisone in an effort to assess their primary capacity for objective response. The two regimens appeared quite comparable in this respect. The 100 patients who had achieved clinical benefit following initial treatment were subsequently randomly allocated to reveive either a fixed alternate treatment program involving the two drug regimens or were continued on the treatment program responsible for their initial improvement. Although those patients who received the fixed alternate treatment shcedule had a somewhat longer progression-free interval compared to the two single-treatment programs (median duration of 16 months versus 12 months, respectively), the three treatment programs including the fixed alternate treatment schedules had comparable median survivals of 21-24 months with little difference noted in survival curves at any point thus far in the analysis. There were no differences noted in survival for the fixed alternating treatment group of patients, with respect to which induction regimen had been utilized to achieve initial response. The toxicity for these treatment programs was tolerable and compatible with outpatient administration. Myelosuppression occurred in the vast majority of patients on either regimen but in both regimens was relatively platelet sparing.

Original languageEnglish (US)
Pages (from-to)219-226
Number of pages8
JournalCancer Clinical Trials
Volume1
Issue number3
StatePublished - Sep 1978
Externally publishedYes

Fingerprint

Breast Neoplasms
Therapeutics
Survival
Melphalan
Prednisone
Fluorouracil
Doxorubicin
Cyclophosphamide
Appointments and Schedules
Outpatients
Blood Platelets
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ahmann, D. L., O'Fallon, J., O'Connell, M. J., Bisel, H. F., Hahn, R. G., Frytak, S., ... Kvols, L. K. (1978). Evaluation of a fixed alternating treatment in patients with advanced breast cancer. Cancer Clinical Trials, 1(3), 219-226.

Evaluation of a fixed alternating treatment in patients with advanced breast cancer. / Ahmann, D. L.; O'Fallon, J.; O'Connell, M. J.; Bisel, H. F.; Hahn, R. G.; Frytak, S.; Edmonson, J. H.; Rubin, J.; Ingle, J. N.; Kvols, L. K.

In: Cancer Clinical Trials, Vol. 1, No. 3, 09.1978, p. 219-226.

Research output: Contribution to journalArticle

Ahmann, DL, O'Fallon, J, O'Connell, MJ, Bisel, HF, Hahn, RG, Frytak, S, Edmonson, JH, Rubin, J, Ingle, JN & Kvols, LK 1978, 'Evaluation of a fixed alternating treatment in patients with advanced breast cancer.', Cancer Clinical Trials, vol. 1, no. 3, pp. 219-226.
Ahmann DL, O'Fallon J, O'Connell MJ, Bisel HF, Hahn RG, Frytak S et al. Evaluation of a fixed alternating treatment in patients with advanced breast cancer. Cancer Clinical Trials. 1978 Sep;1(3):219-226.
Ahmann, D. L. ; O'Fallon, J. ; O'Connell, M. J. ; Bisel, H. F. ; Hahn, R. G. ; Frytak, S. ; Edmonson, J. H. ; Rubin, J. ; Ingle, J. N. ; Kvols, L. K. / Evaluation of a fixed alternating treatment in patients with advanced breast cancer. In: Cancer Clinical Trials. 1978 ; Vol. 1, No. 3. pp. 219-226.
@article{6ffe2c8205fb4c2b9cda424658cf1e4d,
title = "Evaluation of a fixed alternating treatment in patients with advanced breast cancer.",
abstract = "A total of 128 patients were randomly assigned to two induction treatment programs: Adriamycin and L-PAM versus Cytoxan, 5-Fluorouracil, and Prednisone in an effort to assess their primary capacity for objective response. The two regimens appeared quite comparable in this respect. The 100 patients who had achieved clinical benefit following initial treatment were subsequently randomly allocated to reveive either a fixed alternate treatment program involving the two drug regimens or were continued on the treatment program responsible for their initial improvement. Although those patients who received the fixed alternate treatment shcedule had a somewhat longer progression-free interval compared to the two single-treatment programs (median duration of 16 months versus 12 months, respectively), the three treatment programs including the fixed alternate treatment schedules had comparable median survivals of 21-24 months with little difference noted in survival curves at any point thus far in the analysis. There were no differences noted in survival for the fixed alternating treatment group of patients, with respect to which induction regimen had been utilized to achieve initial response. The toxicity for these treatment programs was tolerable and compatible with outpatient administration. Myelosuppression occurred in the vast majority of patients on either regimen but in both regimens was relatively platelet sparing.",
author = "Ahmann, {D. L.} and J. O'Fallon and O'Connell, {M. J.} and Bisel, {H. F.} and Hahn, {R. G.} and S. Frytak and Edmonson, {J. H.} and J. Rubin and Ingle, {J. N.} and Kvols, {L. K.}",
year = "1978",
month = "9",
language = "English (US)",
volume = "1",
pages = "219--226",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Evaluation of a fixed alternating treatment in patients with advanced breast cancer.

AU - Ahmann, D. L.

AU - O'Fallon, J.

AU - O'Connell, M. J.

AU - Bisel, H. F.

AU - Hahn, R. G.

AU - Frytak, S.

AU - Edmonson, J. H.

AU - Rubin, J.

AU - Ingle, J. N.

AU - Kvols, L. K.

PY - 1978/9

Y1 - 1978/9

N2 - A total of 128 patients were randomly assigned to two induction treatment programs: Adriamycin and L-PAM versus Cytoxan, 5-Fluorouracil, and Prednisone in an effort to assess their primary capacity for objective response. The two regimens appeared quite comparable in this respect. The 100 patients who had achieved clinical benefit following initial treatment were subsequently randomly allocated to reveive either a fixed alternate treatment program involving the two drug regimens or were continued on the treatment program responsible for their initial improvement. Although those patients who received the fixed alternate treatment shcedule had a somewhat longer progression-free interval compared to the two single-treatment programs (median duration of 16 months versus 12 months, respectively), the three treatment programs including the fixed alternate treatment schedules had comparable median survivals of 21-24 months with little difference noted in survival curves at any point thus far in the analysis. There were no differences noted in survival for the fixed alternating treatment group of patients, with respect to which induction regimen had been utilized to achieve initial response. The toxicity for these treatment programs was tolerable and compatible with outpatient administration. Myelosuppression occurred in the vast majority of patients on either regimen but in both regimens was relatively platelet sparing.

AB - A total of 128 patients were randomly assigned to two induction treatment programs: Adriamycin and L-PAM versus Cytoxan, 5-Fluorouracil, and Prednisone in an effort to assess their primary capacity for objective response. The two regimens appeared quite comparable in this respect. The 100 patients who had achieved clinical benefit following initial treatment were subsequently randomly allocated to reveive either a fixed alternate treatment program involving the two drug regimens or were continued on the treatment program responsible for their initial improvement. Although those patients who received the fixed alternate treatment shcedule had a somewhat longer progression-free interval compared to the two single-treatment programs (median duration of 16 months versus 12 months, respectively), the three treatment programs including the fixed alternate treatment schedules had comparable median survivals of 21-24 months with little difference noted in survival curves at any point thus far in the analysis. There were no differences noted in survival for the fixed alternating treatment group of patients, with respect to which induction regimen had been utilized to achieve initial response. The toxicity for these treatment programs was tolerable and compatible with outpatient administration. Myelosuppression occurred in the vast majority of patients on either regimen but in both regimens was relatively platelet sparing.

UR - http://www.scopus.com/inward/record.url?scp=0018006781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018006781&partnerID=8YFLogxK

M3 - Article

C2 - 391427

AN - SCOPUS:0018006781

VL - 1

SP - 219

EP - 226

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 3

ER -